

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Amphetamine Products	Page: 1 of 5
Effective Date: 4/16/2025	Last Review Date: 3/2025
Applies to: <div style="display: flex; justify-content: space-between; padding: 0;"> <div> <input type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids </div> <div> <input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia </div> <div> <input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan </div> </div>	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for amphetamine products under the member's prescription drug benefit.

Description:

Adderall

Adderall is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

Adderall XR

Adderall XR is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).

Adzenys ER, Adzenys XR-ODT, Desoxyn, Dyanavel XR

These products are indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.

Dexedrine

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome.

Dextroamphetamine, ProCentra, Zenzedi

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Evekeo

Narcolepsy

Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products

Page: 2 of 5

Effective Date: 4/16/2025

Last Review Date: 3/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Exogenous Obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines should be weighed against possible risks inherent in use of the drug.

Evekeo ODT

Evekeo ODT is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 3 to 17 years of age.

Mydayis

Mydayis is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

Xelstrym

Xelstrym is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

Compendial Uses

Narcolepsy

Applicable Drug List:

Reference Formulary for specific drugs

Policy/Guideline:

Documentation for Initial Requests for all indications:

For non-preferred medication requests, the patient is unable to take three (3) formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

Criteria:

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) **AND**
 - The diagnosis has been appropriately documented (e.g., evaluated by a complete clinical assessment, using DSM-5, standardized rating scales, interviews/questionnaires) **AND**



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products

Page: 3 of 5

Effective Date: 4/16/2025

Last Review Date: 3/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

- The patient is 6 years of age or older
OR
- The patient is 5 years of age or younger
AND
 - The patient continues to have ADHD/ADD (Attention-Deficit/Hyperactivity Disorder or Attention Deficit Disorder) symptoms despite participating in evidence-based behavioral therapy (e.g., parent training in behavior management (PTBM), behavioral classroom interventions)

OR

- The request is for continuation of therapy
AND
- The patient achieved or maintained improvement in their signs and symptoms of ADHD/ADD (Attention-Deficit/Hyperactivity Disorder or Attention Deficit Disorder) from baseline
AND
- The patient's need for continued therapy has been assessed within the previous year

OR

- The patient has a diagnosis of narcolepsy
AND
 - The requested drug is being prescribed by, or in consultation with, a sleep specialist
AND
 - The diagnosis has been confirmed by a sleep study

OR

- The request is for continuation of therapy
AND
- The patient achieved or maintained improvement in daytime sleepiness with narcolepsy from baseline

OR

- The request is for Vyvanse for the treatment of moderate to severe binge eating disorder (BED)
AND
 - The request is for initial therapy

OR



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products Page: 4 of 5

Effective Date: 4/16/2025 Last Review Date: 3/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

- The request is for continuation of therapy
AND
- The patient achieved or maintained improvement in symptoms of BED from baseline
AND
- The patient's need for continued therapy has been assessed within the previous year

Approval Duration and Quantity Restrictions:

Approval: Initial and Renewal - Approve 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Adderall [package insert]. Parsippany, NJ: Teva Pharmaceuticals; May 2024.
2. Adderall XR [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; October 2023.
3. Adzenys XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics Brands, LLC; October 2023.
4. Desoxyn [package insert]. Tampa, FL: Ajenat Pharmaceuticals, LLC; September 2024.
5. Dexedrine Spansule [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; October 2023.
6. Dextroamphetamine sulfate [package insert]. Parsippany, NJ: Teva Pharmaceuticals; September 2023.
7. Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; October 2023.
8. Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2023.
9. Evekeo ODT [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2023.
10. Mydayis [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; October 2023.
11. ProCentra [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; July 2023.
12. Vyvanse [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; October 2023.
13. Xelstrym [package insert]. Miami, FL: Noven Pharmaceuticals, Inc.; October 2023.
14. Zenzedi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; October 2023.
15. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed October 9, 2024.
16. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed October 9, 2024.
17. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 10/09/2024).
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision. Arlington, Virginia: American Psychiatric Association; 2022.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Amphetamine Products

Page: 5 of 5

Effective Date: 4/16/2025

Last Review Date: 3/2025

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

19. Wolraich ML, Hagan JF, Allan C, et al. AAP Subcommittee On Children And Adolescents With Attention-Deficit/Hyperactive Disorder. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528.
20. American Academy of Sleep Medicine. International Classification of Sleep Disorders, Third Edition, Text Revision. American Academy of Sleep Medicine, 2023.
21. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881-1893.